Compare Becton Dickinson and Co (BDX) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs NetFlix Inc — how do they compare? Becton Dickinson and Co trades at $154.5 (market cap $41.51B), while NetFlix Inc trades at $73.96 (market cap $309.62B). The key difference: NetFlix Inc is far larger — about 7.5× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays a 2.79% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| BDX | NFLX | |
|---|---|---|
Market Cap | $41.51B | $309.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.39 | $127.42 |
52-Week Low | $135.49 | $70.91 |
Enterprise Value | $57.97B | $311.69B |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Netflix (NFLX) trades at $73.83, showing modest daily gains of 0.63% but remains in a technical bearish trend. The stock demonstrates strong fundamental performance with Q1 2026 EPS beating expectations at $1.23 versus $0.763 expected, while revenue growth accelerated to 16% year-over-year. Analyst sentiment remains predominantly bullish with 66% buy ratings, though technical indicators signal near-term caution with the stock approaching key support levels.
The investment outlook balances robust fundamentals against technical headwinds. Netflix's expanding advertising business and projected $3 billion in ad revenue by 2026 provide growth catalysts, while competitive pressures and market volatility present risks. With a consensus price target of $103.64 offering 40% upside potential, the stock presents value for long-term investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
